Screener
Vor Biopharma VOR Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Vor Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Vor Biopharma’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 8:31 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-220689
| (in thousands, except share and per share amounts) | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Interest income | 3,935 | 805 |
| Change in fair value of warrant liabilities | (188,360) | — |
| Total other (expense) income | (184,425) | 805 |
| Net loss | $(219,585) | $(32,486) |
| Net loss per share attributable to common stockholders, basic and diluted(1) | $(5.11) | $(5.21) |
| Weighted-average common shares outstanding, basic and diluted(1) | 43,011,544 | 6,241,207 |
| Other comprehensive income (loss): | ||
| Unrealized (loss) gain on available for sale marketable securities | (747) | 1 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Vor Biopharma's net income?
- Vor Biopharma (VOR) reported net income of -$219.59M in Q1 2026.
- How has Vor Biopharma's net income changed year-over-year?
- Vor Biopharma's net income decreased by 575.9% year-over-year, from -$32.49M to -$219.59M.
- What is the long-term trend for Vor Biopharma's net income?
- Over 3 years (2021 to 2024), Vor Biopharma's net income has grown at a 19.3% compound annual growth rate (CAGR), from -$68.9M to -$116.91M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Vor Biopharma's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude